Seminars in Oncology
Volume 33, Supplement 3 , Pages 7-10, February 2006

Therapeutic Advances in Cutaneous T-Cell Lymphoma (CTCL): From Retinoids to Rexinoids

  • Rudolf Stadler

      Affiliations

    • Corresponding Author InformationAddress correspondence and reprint requests to Prof Rudolf Stadler, MD, Hautklinik, Klinikum Minden, Portastr. 7-9, 32423 Minden, Germany
  • ,
  • Almut Kremer

Hautklinik, Klinikum Minden, Germany

Retinoids comprise a family of polyisoprenoid lipids that include vitamin A (retinol) and its various natural and synthetic analogues. Retinoids are compounds with multiple actions. They are involved in the control of cell proliferation, cell differentiation, and embryonic development. Each retinoid has its own profile of pharmacologic properties that determines its usefulness in clinical dermatology or oncology. Although numerous synthetic retinoids have been synthesized, their biological activities are usually associated with clinical disadvantages such as toxicity and teratogenicity. Retinoids that bind to both the retinoic acid receptor and retinoid X receptor subtypes have shown clinical activity in hematologic malignancies and can mediate genes associated with both growth and differentiation. Retinoid X receptor-specific rexinoids have also shown efficacy in the treatment of cutaneous T-cell lymphomas, but their exact mechanism of action is unclear. This article summarizes the clinical relevance of both groups of compounds in this important patient population.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This supplement was supported by an unrestricted educational grant from Zeneus Pharma Ltd.

PII: S0093-7754(05)00510-5

doi:10.1053/j.seminoncol.2005.12.016

Seminars in Oncology
Volume 33, Supplement 3 , Pages 7-10, February 2006